16 recruiting, 5 active not recruiting, 4 withdrawn, 3 terminated. 22 Phase 2, 9 Phase 1, 2 Phase 3.
Follow Cemiplimab-Rwlc: new trials by email Literature Review of Cemiplimab-Rwlc trials Research Report on Cemiplimab-Rwlc
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC) Cemiplimab - Colon and Rectal Cancer | Phase 2 | Recruiting | Columbia University | 20 | 2027-01-01 | 2026-11-04 |
| Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma Actinium Ac 225 Lintuzumab, Biospecimen Collection, Cemiplimab - Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 30 | 2026-12-04 | 2026-06-12 |
| Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features Cemiplimab-Rwlc - Non-small Cell Lung Cancer Stage III | Phase 2 | Recruiting | Georgetown University | 21 | 2026-11-01 | 2026-10-06 |
| Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma Biopsy Procedure, Biospecimen Collection, Carboplatin - Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 108 | 2026-09-01 | 2026-10-05 |
| Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer Biospecimen Collection, Cemiplimab, Cetuximab Sarotalocan Sodium - Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2026-08-15 | 2026-09-15 | |
| Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer Biopsy Procedure, Biospecimen Collection, Cemiplimab - Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 86 | 2026-08-10 | 2026-09-09 |
| Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 44 | 2026-05-27 | 2026-10-26 |
| Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer Biospecimen Collection, Carboplatin, Cemiplimab - Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 180 | 2026-04-24 | 2026-10-26 |
| Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer Biospecimen Collection, Cabozantinib, Cemiplimab - Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 48 | 2026-02-22 | 2026-11-06 |
| Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer Biopsy, Biospecimen Collection, Cemiplimab - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 11 | 2026-01-30 | 2026-05-20 |
| Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma Biopsy Procedure, Biospecimen Collection, Cemiplimab - Metastatic NUT Carcinoma, Unresectable NUT Carcinoma | Phase 2 | Recruiting | Northwestern University | 15 | 2025-08-15 | 2026-08-18 |
| Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) Biospecimen Collection, Cemiplimab, Computed Tomography - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 / Phase 3 | Recruiting | SWOG Cancer Research Network | 378 | 2025-05-22 | 2026-10-09 |
| Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer Biospecimen Collection, Cemiplimab, Fianlimab - Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 60 | 2025-05-02 | 2026-10-29 |
| Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer Biospecimen Collection, Cemiplimab, Computed Tomography - Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain | Phase 2 | Withdrawn | City of Hope Medical Center | 2025-04-15 | 2025-05-26 | |
| Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy Atezolizumab, Biospecimen Collection, Cemiplimab - Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | Emory University | 20 | 2025-04-09 | 2026-02-12 |
| Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer Biospecimen Collection, Cemiplimab, Computed Tomography - Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma | Phase 3 | Suspended | National Cancer Institute (NCI) | 420 | 2025-02-18 | 2026-11-03 |
| Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma | Phase 1 | Recruiting | Mayo Clinic | 21 | 2024-01-05 | 2026-07-01 |
| Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery Cemiplimab, Computed Tomography, Biospecimen Collection - Locally Advanced Basal Cell Carcinoma, Basal Cell Carcinoma | Phase 2 | Suspended | Thomas Jefferson University | 70 | 2023-07-05 | 2026-06-10 |
| Cemiplimab/Peg-Interferon-α in Advanced CSCC Cemiplimab-Rwlc, PEG-IFN alfa-2a - Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma | Phase 1 | Withdrawn | Baptist Health South Florida | 2023-07-01 | 2023-08-09 | |
| Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) Cemiplimab-Rwlc - Head and Neck Squamous Cell Carcinoma, HNSCC | Phase 2 | Withdrawn | University of Miami | 2022-07-01 | 2022-08-04 |
Showing 20 of 31. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (7) · Lung Neoplasms (5) · Laryngeal Neoplasms (3) · Mouth Neoplasms (3) · Skin Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Carcinoma (2) · Glioblastoma (2) · Lymphoma, Large-Cell, Anaplastic (2) · Lymphoma, T-Cell (2) · Mycosis Fungoides (2) · Oropharyngeal Neoplasms (2) · Adrenocortical Carcinoma (1) · Brain Neoplasms (1) · Breast Neoplasms (1)
National Cancer Institute (NCI) (7) · Mayo Clinic (3) · City of Hope Medical Center (2) · Emory University (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · M.D. Anderson Cancer Center (2) · University of Southern California (2) · Alaunos Therapeutics (1) · Baptist Health South Florida (1) · Columbia University (1) · Georgetown University (1) · Marcelo Bonomi (1) · Northwestern University (1) · Roswell Park Cancer Institute (1) · SWOG Cancer Research Network (1)
United States (28) · Australia (1) · Canada (1)
Gino K In, MD (2) · Ahmad Tarhini, MD, PhD (1) · Arya Amini (1) · Bhavana Konda (1) · Christine H Chung, MD (1) · Chukwuemeka Ikpeazu, MD (1) · Guilherme Rabinowits, M.D. (1) · Jaymes Holland (1) · Jennifer W Carlisle (1) · Jochen H Lorch, MD (1) · Jonathan Kessler (1) · Joselle Cook, M.B.B.S. (1) · Joseph Curry, MD (1) · Joshua Reuss, MD (1) · Kah Whye Peng, PhD (1)
PMID 35175355, PMID 34187851, PMID 34850166, PMID 36898933, PMID 41137728
P30CA014089 (2), P30CA033572 (2), P30CA138292 (2), P50CA186781 (2), R01CA262613 (2), U10CA180868 (2), UM1CA186691 (2), P30CA012197 (1), P30CA060553 (1), U10CA180821 (1), U10CA180888 (1), UM1CA186690 (1), UM1CA186712 (1)